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INTRODUCTION
Dr. Eli Glatstein has been an important mentor and friend
during my 30 years in clinical radiation oncology. He has
made countless contributions to our field, and those contri-
butions are being celebrated as part of this special issue of
The Oncologist. I am indebted to him for his guidance and
help in the development of my career generally. I am par-
ticularly grateful to Eli for helping me to form my views
regarding the role of clinical trials as a guide to clinical
medicine.AswellasanyoneIknow,Elicouldpenetratethe
subtleties, the contradictions, the strengths, and the weak-
nesses of the clinically oriented scientific literature. It is
that ability that has made him such a superb teacher and
clinical scientist. That ability (along with many others) has
had an enormous influence on me and has helped generate
the ideas described below. I herein describe some of my
thoughtsandopinions,andtheirrationale,onclinicaltrials.
SomeofthemEliwillagreewith,andsomehewillnot.But
all reflect his teaching to think carefully about these impor-
tant issues.
Clinical oncology is rapidly changing. Rapid introduc-
tion of newer, more sophisticated diagnostic tools, pharma-
ceuticals, and therapeutic technologies increases options
for our patients. This can lead to confusion because it is of-
ten not clear when and if these new treatment options
shouldbeused.Oneofthemostimportantthingsweneedto
do as physicians is to learn how to understand and interpret
conflicting data and information in the medical literature.
Herein, I discuss some of those issues, as they apply to on-
cology in general and specifically to radiation oncology.
Good clinical trials are important to help the clinician
knowwhenandhowtoemploythesenew,oftenexpensive,
diagnostic/therapeutic options. Nevertheless, many tools
reach the clinic without meaningful clinical efficacy data.
In order to be approved in the medical marketplace in the
U.S., devices only have to demonstrate that they accom-
plish the goals for which they are intended, and that is often
a technical, not a clinical endpoint. New drugs have a
greater hurdle in that they need to demonstrate some mea-
sure of clinical efficacy, although the definition of efficacy
isfarfromstraightforward.Attimesnodataareavailableto
demonstrate clinical efficacy, but at times, even when data
are available, they are often suboptimal for several reasons.
CHOOSING THE RIGHT ENDPOINTS FOR
CLINICAL STUDIES
A central problem in many clinical outcome studies is the
definition of benefit. The term is used loosely, and there is
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statistical differences between therapies. Modest improve-
ments in median survival, while statistically significant,
may not be clinically meaningful because any small gain in
survival may be offset by the cost, inconvenience, and tox-
icity of the additional therapy. Median survival reflects
onlyasinglepointonthesurvivalcurve(i.e.,thetimewhen
50% of the patients are alive). Prolongation of median sur-
vival often reflects only a transient increase in survival that
does not translate into long-term benefits. Even that benefit
may accrue to only a small subset of patients.
Themoststringentendpointissurvival,andspecifically
long-term survival. When a larger number of patients sur-
vives beyond some long endpoint (5 years, for example),
thereisaverystrongexpectationthatthepatienthasindeed
been helped by the therapy. The hazard ratio (risk for death
in the experimental versus control arms) is a useful mea-
sure.However,itdoesnotprovideasenseofthemagnitude
of the benefit on an absolute scale, only on a relative scale.
Therefore,ifthebaselinesurvivalisverygood,averysmall
absolute decline in the death rate can lead to a hazard ratio
much less than 1.0, erroneously suggesting a large clinical
benefit. (For example, reducing the absolute risk for death
from 10% to 8% is a hazard ratio of 0.8, or a 20% reduction
in the risk for death. Reducing the absolute risk for death
from 1% to 0.8% produces the same hazard ratio.) The pro-
gression-free rate is another metric of some value. It is less
robustthansurvivalbecauseitisheavilydependentonhow
oftenoneevaluatesforprogression.Further,improvements
in progression-free survival may not lead to improvements
in overall survival.
Radiation oncologists deal primarily with issues of lo-
cal-regionalcontrolofcancer.Therelationshipbetweenlo-
calcontrolandsurvivalisnotalwaysclear.Inbreastcancer,
many individuals thought that local control was a minor is-
sue, and that improved local control did not translate into
longer survival. However, recent data clearly show that im-
provements in local-regional control do translate into sur-
vival benefits, but not in a one-to-one manner. In patients
undergoing breast conservation therapy with lumpectomy
and radiation, approximately 25% of the improvement in
localcontrolaffordedbytheradiationtranslatesintoasurvival
advantage(i.e.,anabsoluteimprovementof20%inlocalcon-
trol produces about a 5% survival improvement) [1].
In some other diseases (e.g., soft tissue sarcomas, rectal
cancer), although it is obvious that local control is neces-
sary for cure, improvements in local control have not di-
rectly resulted in longer survival [2, 3].
The lack of a correlation in these diseases could be re-
lated to the fact that patients who are likely to develop local
failure are also likely to develop distant disease, although
clearlyapatientcannotbecuredunlesstheyhavecontrolof
their local disease as well as their distant disease—local
failure will eventually lead to uncontrolled tumor. At times
localfailuredoesnottranslateintoasurvivaladvantagebe-
cause effective salvage therapy is available (for instance,
amputation for an extremity soft tissue sarcoma or abdom-
inoperineal resection for a rectal cancer), although with the
obvious sequelae of the additional therapy. Other times no
survival advantage will be noted because patients have not
been followed for a long enough time. Survival curves in
rectal cancer often just begin to separate at 3 years and are
not pronounced until 5 years [4].
Another metric to assess clinical efficacy is quality of
life. Because a local recurrence can be morbid, quality of
life assessments may be useful for radiation oncologists. A
major problem with quality of life assessments, and the as-
sociated measure of quality-adjusted life years, is that they
are time-consuming and expensive to obtain, and thus are
often not incorporated into clinical trial design. Neverthe-
less, these analyses provide a way to combine survival du-
ration with the palliative and toxic effects of therapy, into
one relatively simple metric.
Cost-effectiveness is yet another way to quantify clini-
calefficacy.Withthegreatinterestindecreasingthecostof
therapy, measuring the incremental cost divided by the in-
cremental benefit (cost-effectiveness) of one therapy com-
pared with another may hold greater importance in the
future. The challenge to the researcher is to determine how
best to use these various measures to define the best thera-
pies for our patients.
Radiation oncologists are placed in a vulnerable posi-
tion because we use expensive technology and because we
direct our therapy against local-regional disease and not
systemic control. The advances in radiation oncology have
beenenormousoverthepastfewdecades—improvedtarget
definition with better imaging from modalities such as flu-
orodeoxyglucose positron emission tomography scans [5],
conformal radiation dose delivery, and other three-dimen-
sional treatment delivery tools, and better integration of ra-
diationtherapywithsurgeryandchemotherapy[6].Insome
anatomical sites, precise dose localization with dose esca-
lation has provided further improvements such as with ra-
diosurgery [7, 8]. Despite the apparent benefits of these
interventions, we need clinical trials to assess objectively
the utility of our advanced radiation planning/delivery
systems.
INTERPRETATION OF CLINICAL TRIALS
There is a huge amount of literature that is available on vir-
tually any medical topic, but this can at times be more con-
fusing than helpful. Information can be anecdotal and just
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physician, the data can reflect a series of patients treated in
a specific manner or can represent a prospective random-
ized trial. It is generally believed by physicians that ran-
domized trials represent the best clinical information to
determine the value of a therapy. However, when multiple
clinical trials are run, too often they disagree in their mea-
surementofoutcomes,andthiscausesgreatdifficultyinde-
termining what represents “truth.” Commonly, individual
physicians accept as truth those studies that most closely
conform to their preconceptions and find reasons to dis-
count other trials.
The disagreements among trials can be that some stud-
ies are positive and others are indeterminate or that they
clearly disagree. The field of meta-analysis is needed be-
cause individual trials either do not have enough power to
answeraquestionortheyarefranklydiscordant.Forexam-
ple, there are data suggesting that postoperative irradiation
for breast cancer is detrimental in terms of long-term sur-
vival, but other data suggest a survival advantage. Data
from the U.S. show a survival advantage for adjuvant che-
motherapy in rectal cancer, but a number of European stud-
ies have not demonstrated a similar benefit.
Fortunately, clinical trial results are often concordant,
and we are comforted that our decisions are made on strong
evidence. But what do we do when studies are discordant,
especially when the studies seem to be well performed?
There are several possible reasons that different trials, ad-
dressing similar questions, produce different results.
The Endpoints Are Not the Same
Often the results of trials are simplified to the issue of
whether a therapy produces a benefit, but as discussed
above, “benefit” can be defined in many ways. With radia-
tion therapy, one can evaluate survival, disease-free sur-
vival, local control, symptom control, etc., and each of
these endpoints can be measured at multiple different time
points. Short-term endpoints may provide different results
than longer-term endpoints. Some physicians accept the
value of obtaining local control as a critically important
measureofbenefit,whereasothersmayviewsurvivalasthe
only outcome that truly matters and the only outcome that
can be measured with certainty. In general, differences in
local control can be detected at shorter follow-up intervals
than differences in overall survival. The presence of multi-
ple possible measures of outcome can produce heterogene-
ity in the results of clinical trials.
The Patients Are Not the Same
Studies are designed with entry criteria that are often fairly
broad. An adjuvant therapy trial might have entry criteria
that include patients with relatively early-stage disease as
well as those with more advanced disease, but the patients
who are actually included in a study could strongly empha-
sizeonegroupoveranother.Thiscouldresultinatreatment
that is beneficial for a patient subset being swamped by the
lack of value in a larger patient subset. The difference in
patient composition can vary greatly among trials.
There also can be major differences in patient popula-
tionsrelatedtowhichpatientsdecidetoenterastudy.Entry
criteria can strongly select for a group of patients who are
not representative of all patients with that disease. For in-
stance,ifatreatmentisviewedasespeciallytoxic,thatmay
result in physicians entering only their highest risk patients
into the study, even if patients with lower risk disease are
eligible. Entry criteria can also be restrictive in a way that
can cause an imbalance in patients actually being placed in
a study. A possible example of this is the gastric cancer in-
tergroup trial of adjuvant radiation therapy and chemother-
apy after surgical resection. The entry criteria for that study
required good nutrition 1 month after surgery. Patients who
have more extensive gastric resections are less likely to be
doingwellnutritionallyatthistime,sothestudycouldhave
biased entry to patients who had less aggressive surgical
therapy [9].
Inaddition,therecanbedifferencesinpatiententryinto
different clinical trials related to local practice patterns,
both regional differences within a country and practice dif-
ferencesacrossmultiplecountries.Thesecouldrelatetothe
use of different standard operative procedures, different
staging techniques (or different interpretation of the same
staging technique), or varying use of chemotherapy, etc. In
the extreme, there are differing definitions of what patho-
logical findings constitute an invasive cancer versus a non-
invasive cancer, or what pathology defines an intermediate
orhigh-gradetumor(suchasasarcoma)versusalow-grade
tumor. Formal analyses have been performed on the varia-
tion in pathologist subclassification of both sarcomas and
lymphomas,andtheseoftendemonstrateadiscordancerate
of approximately one third [10, 11]. These are not trivial
differences and can have an enormous influence on treat-
ment outcome and the results of a clinical trial.
Patient Evaluation Is Not the Same
Different tests, ostensibly measuring the same parameter,
can produce different results. This can occur either at the
time of patient enrollment in a trial or during the conduct of
a trial while evaluating response or tumor control. A mag-
netic resonance imaging (MRI) scan of the liver to evaluate
a patient for metastatic disease will produce somewhat dif-
ferentresultsthanacomputedtomographyscanoftheliver,
and even different MRI scans will produce differing results
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usually viewed as the gold standard in many clinical situa-
tions. In addition to variation in defining the diagnosis,
pathological evaluation can also affect the stage and extent
of disease. Pathologists who analyze a large number of
lymph nodes after a bowel resection are more likely to find
nodal metastases and that finding can dramatically change
the tumor stage and thus who enters a clinical trial or how
those patients are stratified [12].
There is an additional problem now with more sophis-
ticated studies for evaluating the presence of tumor in a
specimen. Immunohistochemistry (IHC) can identify very
smallclustersoftumorcells,andtheseevaluationsaredone
to varying extents in different institutions. It is likely that
the patients who are node positive in breast cancer studies
today are a substantially different population than node-
positive patients in earlier studies, with a substantial stage
migrationfromimprovedpathologyandIHC.Inadditionto
alteringentryintoaclinicaltrial,thisinformationcanaffect
study outcome directly if one is evaluating the pathological
complete response rate, an endpoint that now becomes
heavily dependent on the vigilance of the pathologist (who
may have little interest in the clinical trial).
The Treatments Are Not the Same
Although we have made much progress in standardizing
therapy over the past few decades, there are aspects of care
that are very difficult to standardize. Chemotherapy tends
to be the easiest of the standard oncologic interventions to
make uniform, because there is little technical variation in
treatment delivery—a dose of 1 g of a drug into a vein can-
not be varied much among centers.
The other extreme is surgical management, for which
quality control is usually determined by some combination
of reading an operative report and reading a pathology
report. Neither document is all that reliable and at best
provides secondhand evidence of what surgery was accom-
plished. There have been a few attempts to standardize sur-
gery in the context of randomized trials, specifically in the
AmericanCollegeofSurgeryOncologyGroup(ACOSOG)
studies of laparoscopic surgery, in which surgeons had to
both demonstrate an adequate volume of cases and have
video recordings of their operations screened for technical
expertise [13].
This is difficult and expensive to implement in most sit-
uations(especiallyinstudiesofadjuvanttherapiesinwhich
the surgery may have been completed prior to entry into a
clinical trial even being considered). The value of an adju-
vant therapy can be heavily dependent on what operation
was actually accomplished for patients in those studies.
Radiation therapy tends to be in-between the situations
of surgery and chemotherapy. Radiation treatment plans
can be reviewed and the quality of machine calibration can
be determined. However, because radiation oncology is a
technically oriented field, there can still be large variations
in implementation. Despite attempts at uniformity, the def-
inition of dose delivered is variable. When one evaluates
studies of intensity-modulated radiation therapy for pros-
tate cancer, doses can be quoted at isocenter, as a minimal
tumor dose, or as some other parameter, and that can pro-
duce substantially different dose prescriptions for what ap-
pears to the inexperienced reader to be the same treatment.
Evenifoneweretomakethedosedefinitionuniformacross
centers, because different techniques are used to obtain that
dose the actual dose delivered to varying portions of the tu-
mor could vary among institutions. In addition, it has been
shown that anatomic structures, especially tumor volumes,
are contoured differently in different centers [14, 15].
Insomeanatomiclocations,evensmallvariationsinthe
definitionofaclinicaltargetvolumecanresultinmajordif-
ferences in treatment delivered. Although tumor targets are
likely to be the areas with the greatest contour definition
variation, problems also occur with normal tissue. For ex-
ample, how much of the rectum (from proximal to distal) is
contoured and how it is contoured (just the wall or the lu-
men also) when designing a treatment for prostate cancer
with radiation therapy vary widely. Many institutions de-
fine the rectum over the range (with a 1- to 2-cm margin) of
the rectum that will be in the radiation field. In this situa-
tion, there is likely to be a paradoxical effect of showing
that the percentage of rectum being treated to high dose is
lowerwhenlargerfieldsareused,eventhoughmorerectum
is being irradiated. There are other examples of similar ef-
fects, but it is important to realize that tumor and normal
tissue volumes can be retrospectively adjusted to produce
the dose distributions that one desires. Mathematical preci-
sion does not necessarily imply accuracy or uniformity.
The Statistical Evaluation Is Not the Same
Biostatisticians at times do not agree on the best techniques
to use when evaluating a clinical trial. Even simple issues
such as whether to do a one-sided or a two-sided statistical
test can easily turn a negative trial into a positive one (and
viceversa).Thisdoesnotmeanthatoneapproachiscorrect
andtheotheriswrong,butratherthatthereisadifferenceof
opinion that can lead to differing conclusions as to the
meaning of a statistical result. In addition, although most
statisticiansagreethatsubsetanalysesshouldbehypothesis
generating, subsets are at times analyzed as if they are pro-
viding definitive information.
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Given the large number of ways in which clinical trials
dealing with the same topic can vary, it is almost surprising
thatweseeconcordanceasoftenaswedo.Ofcourse,thisis
because if the therapeutic difference is large enough (or
small enough), the differences (or lack of them) will dom-
inatetheresults.Whatdoesonedowhenfacedwithapleth-
ora of contradictory data? One approach that is commonly
usedistodometa-analyses,orsimilaranalyses,ofmultiple
randomized clinical trials. This has the benefit of amassing
alargeamountofdataintoasingleusableformat.However,
it has the distinct disadvantage that, unless the analysis is
carefullyconstructed,poordataincludedintheanalysiscan
skew the results. In addition, if one or two large trials dom-
inate the results of the meta-analysis, any of the issues dis-
cussed above can have a major effect on the conclusions.
Thus,asistrueformedicinegenerally,ifgooddataareused
toperformthemeta-analysis,theresultsarelikelytobeuse-
ful and meaningful. However, the analysis is no better than
the data that go into it.
We must also be fully cognizant that a statistical differ-
ence in results between treatments does not necessarily
mean that there is a “meaningful” clinical benefit. There is
virtually always a tradeoff between side effects and toxici-
tiesoftherapyandthebenefitobtained.Astudyofaddinga
biological therapy to chemotherapy in pancreatic cancer
produced an improvement in the median survival time of
2 weeks, a difference that was statistically significant
[16]. Many would argue that this difference is too small to
be clinically meaningful, but perhaps a more impressive
difference would have been noted by evaluating the 1-year
survival rate or quality-of-life endpoints.
In the present health care system, and with proposed
changestothatsystem,onemustaskwhetherthebenefitsof
specific therapies are outweighed by the financial costs of
the intervention. As discussed at the beginning of this arti-
cle, there are many measures of benefit, but no generally
agreed upon metrics outside the straightforward metric of
long-term survival. But survival, as important as it is, is not
the only meaningful measure. Determining quality of life
parametersisimportant,butwilliteverbepossibleforusto
determine the value of a quality-adjusted life year?
Thus,thereisnoshortcuttoobtainthe“truth”inanswer
to a question, and even with the most careful analysis the
answersareoftenambiguous.Onehastodomorethanread
the conclusions of an article to determine if the conclusions
in an abstract are valid. The answers to “how good a study
is,” and to understand the appropriate conclusions, come
from careful reading of the study design and analysis, and
understanding the specific questions that are answered in
the clinical trial and the answers that are pertinent for the
patient who one is seeing at that time.
There is a real risk in this approach. It is all too easy for
our own biases to creep into the decision of which clinical
trials are done correctly, and which analyses are meaning-
ful. The human mind does a wonderful job of forcing facts
to support our preconceptions. Despite our earnest desires
to the contrary, we are all a product of our training and our
environment. It is too easy for a medical oncologist to de-
cide that a short extension of life span is clinically mean-
ingful. It is too easy for a radiation oncologist to be
convinced that improving local control in all situations will
produce a benefit to the patient. It is too easy for a surgeon
to be convinced that resecting another metastasis will im-
prove a patient’s quality of life. All physicians need to de-
velop expertise in their chosen specialty and subspecialty,
but physicians who do not have a broad understanding of
patients, and the entire diagnostic and therapeutic environ-
ment, will not be able to understand the subtleties of many
clinical trials, and will not be able to make the proper clin-
ical judgments.
EliGlatsteindidnotparticipateinmyformaltrainingas
aphysician.ItookmyfirstjobwithEliattheNationalCan-
cer Institute (NCI) after completing military service in the
Air Force. However, Eli was a true mentor to me as a junior
attending physician at the NCI, and did what a mentor is
supposed to do—allow an individual to develop his/her
skills and interests so that they can succeed in their career.
Eli Glatstein was, and is, the consummate clinician, and so
much of what is discussed above comes directly from the
things that Eli taught me and so many other young faculty
members. He always knew that the data were most impor-
tant, but that data taken out of context were of little value.
Elihasneverbeenafanofmeta-analysisbecauseitsooften
did just that—separated the mathematical analysis of out-
comes from the patient and ignored the careful evaluation
of the strengths and weaknesses of individual trials. Al-
though Eli should not be blamed for any of the comments
above, he should be credited for those portions that are
meaningful and helpful, because he was the genesis of so
many of these ideas.
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